Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

Circulation - United States
doi 10.1161/circulationaha.106.668020
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Rivaroxaban: An Oral Direct Inhibitor of Factor Xa

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2008English

Management of Acute Proximal Deep Vein Thrombosis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2002English

Editorial: Endovascular Treatment for Acute Proximal Deep Vein Thrombosis

Journal of Cardiology Cases
Cardiovascular MedicineCardiology
2015English

Remarkable Regression of Massive Deep Vein Thrombosis in Response to Intensive Oral Rivaroxaban Treatment

Thrombosis Journal
Hematology
2015English

Effect of Famotidine on the Pharmacokinetics of Apixaban, an Oral Direct Factor Xa Inhibitor

Clinical Pharmacology: Advances and Applications
Pharmacology
2013English

Safety, Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – In Elderly Chinese Subjects

Thrombosis and Haemostasis
Hematology
2010English

Antithrombotic Drug and Its Clinical Indication. Factor Xa Inhibitor. Oral Xa Inhibitor (DX-9065a).

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1996English

Deep Vein Thrombosis

JAMA - Journal of the American Medical Association
Medicine
2015English

Deep Vein Thrombosis

AAOHN Journal
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy